Inovio Pharmaceuticals Inc vs The Coca-Cola Co K — how do they compare? Inovio Pharmaceuticals Inc trades at $0.78 (market cap $76.09M), while The Coca-Cola Co K trades at $86.5 (market cap $373.76B). The key difference: The Coca-Cola Co K is far larger — about 4912.1× Inovio Pharmaceuticals Inc's market cap, and The Coca-Cola Co K pays a 2.44% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | KO | |
|---|---|---|
Market Cap | $76.09M | $373.76B |
Sector | Health | Consumer Staples |
52-Week High | $2.87 | $89.08 |
52-Week Low | $0.66 | $65.67 |
Enterprise Value | $47.10M | $400.93B |
Volume | — | 14,630,257 |
Dividend Yield | — | 2.44% |
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.668, down 0.86% with bearish technical signals despite recent earnings beats. The company shows minimal revenue of $65,340 against substantial losses, with negative margins and cash flow challenges. Key catalyst is the FDA's October 2026 decision on INO-3107, while recent $20 million offering aims to fund operations.
High-risk biotech play with binary FDA outcome driving valuation. Analyst consensus is bullish (53% buy) with $3.25 price target, but fundamental weaknesses and litigation risks require caution. Success of INO-3107 is critical for turnaround, with current cash funding operations into early 2027.
Coca-Cola (KO) trades at $86.87, down 0.21% on the day, with a bullish technical signal supported by moving averages and RSI near oversold levels. The company shows strong profitability with a 28.56% net income margin and consistent earnings beats, while analyst consensus is a Buy with a $95.83 price target. Recent news highlights institutional accumulation and stable dividend trends.
The outlook remains positive given earnings momentum and dividend reliability, though risks include regional demand divergence and high valuation multiples. Upside is supported by analyst targets and institutional confidence, but investors should weigh debt levels and competitive pressures in the beverage sector.
Trailing returns across standard periods
Latest headlines on both assets
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →